Stay updated on Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    No substantive changes to study details, eligibility criteria, endpoints, or enrollment were detected; any differences appear to be minor formatting and layout updates. These non-substantive changes do not affect the page's core purpose of conveying trial information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-10-27T20:52:37.000Z thumbnail image
  3. Check
    32 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T07:51:38.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. No other page content appears affected.
    Difference
    0.1%
    Check dated 2025-09-29T04:10:01.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Updated page revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element.
    Difference
    0.2%
    Check dated 2025-09-14T21:47:23.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T18:15:09.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new medical terms related to treatment techniques. Notably, the drug pembrolizumab has been reintroduced, indicating a focus on specific therapeutic options.
    Difference
    2%
    Check dated 2025-08-31T12:20:48.000Z thumbnail image

Stay in the know with updates to Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- SBRT in Stage IV NSCLC Clinical Trial page.